Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)′: ##STR00001##
wherein A is S or O; R.sup.1a is substituted or unsubstituted alkyloxy or the like, R.sup.2a to R.sup.2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R.sup.3 is each independently halogen or the like, r is an integer of 0 to 4, R.sup.4 is substituted or unsubstituted aromatic heterocyclyl or the like,
or a pharmaceutically acceptable salt thereof.

The present invention relates to a cannabinoid containing oral solution. Preferably the cannabinoid is cannabidiol (CBD), cannabidivarin (CBDV) or cannabidiol-C4 (CBD-C4). More preferably the CBD, CBDV or CBD-C4 is present at a concentration of between 25 and 75 mg/ml. More preferably still the CBD, CBDV or CBD-C4 is present at a concentration of 50 mg/ml. In a further embodiment the oral solution is formulated with one or more edible oils. Preferably the edible oil is sesame oil. It is a preferred embodiment of the invention that the oral formulation comprises a low concentration of ethanol.

A method of treating a patient with a psychedelic, by administering either a dose of LSD to the patient that is equivalent to a known dose of psilocybin with desired acute and therapeutic effects, or administering a dose of psilocybin to the patient that is equivalent to a known dose of LSD with desired acute and therapeutic effects. A method of treating a patient with LSD, by administering a dose of LSD to the patient equivalent to those of psilocybin known to be associated with positive long-term therapeutic outcomes. A method of determining a dose of a psychedelic or the dose-equivalence to another psychedelic to be administered to an individual, by administering a dose of a psychedelic to an individual, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual.

Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).

Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).

The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.

The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.

The invention relates to besylate salts of the compound of formula (I):

##STR00001##

Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.

A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro.sup.36Exendin-4(1-39)-Lys.sub.6-NH.sub.2 or/and a pharmaceutically acceptable salt thereof, and (b) a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.